Xin-Yu Xiong1, Xiao Liu, Yuan-Ding Chen. 1. The Key Laboratory, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650118, Yunnan Province, China.
Abstract
AIM: To develop the epitope-based vaccines to prevent Hepatitis C virus (HCV) / Hepatitis B virus (HBV) infections. METHODS: The HCV core epitopes C1 STNPKPQRKTKRNTNRRPQD (residuals aa2-21) and C2 VKFPGGGQIVGGVYLLPRR (residuals aa22-40), envelope epitope E GHRMAWDMMMNWSP (residuals aa315-328) and HBsAg epitope S CTTPAQGNSMFPSCCCTKPTDGNC (residuals aa124-147) were displayed in five different sites of the flock house virus capsid protein as a vector, and expressed in E. coli cells (pET-3 system). Immunoreactivity of the epitopes with anti-HCV and anti-HBV antibodies in the serum from hepatitis C and hepatitis B patients were determined. RESULTS: The expressed chimeric protein carrying the HCV epitopes C1, C2, E (two times), L3C1-I2E-L1C2-L2E could react with anti-HCV antibodies. The expressed chimeric protein carrying the HBV epitopes S, I3S could react with anti-HBs antibodies. The expressed chimeric proteins carrying the HCV epitopes C1, C2, E plus HBV epitope S, L3C1-I2E-L1C2-L2E-I3S could react with anti-HCV and anti-HBs antibodies. CONCLUSION: These epitopes have highly specific and sensitive immunoreaction and are useful in the development of epitope-based vaccines.
AIM: To develop the epitope-based vaccines to prevent Hepatitis C virus (HCV) / Hepatitis B virus (HBV) infections. METHODS: The HCV core epitopes C1 STNPKPQRKTKRNTNRRPQD (residuals aa2-21) and C2 VKFPGGGQIVGGVYLLPRR (residuals aa22-40), envelope epitope E GHRMAWDMMMNWSP (residuals aa315-328) and HBsAg epitope S CTTPAQGNSMFPSCCCTKPTDGNC (residuals aa124-147) were displayed in five different sites of the flock house virus capsid protein as a vector, and expressed in E. coli cells (pET-3 system). Immunoreactivity of the epitopes with anti-HCV and anti-HBV antibodies in the serum from hepatitis C and hepatitis Bpatients were determined. RESULTS: The expressed chimeric protein carrying the HCV epitopes C1, C2, E (two times), L3C1-I2E-L1C2-L2E could react with anti-HCV antibodies. The expressed chimeric protein carrying the HBV epitopes S, I3S could react with anti-HBs antibodies. The expressed chimeric proteins carrying the HCV epitopes C1, C2, E plus HBV epitope S, L3C1-I2E-L1C2-L2E-I3S could react with anti-HCV and anti-HBs antibodies. CONCLUSION: These epitopes have highly specific and sensitive immunoreaction and are useful in the development of epitope-based vaccines.
Authors: B Robertson; G Myers; C Howard; T Brettin; J Bukh; B Gaschen; T Gojobori; G Maertens; M Mizokami; O Nainan; S Netesov; K Nishioka; T Shin i; P Simmonds; D Smith; L Stuyver; A Weiner Journal: Arch Virol Date: 1998 Impact factor: 2.574
Authors: K G Hadlock; R E Lanford; S Perkins; J Rowe; Q Yang; S Levy; P Pileri; S Abrignani; S K Foung Journal: J Virol Date: 2000-11 Impact factor: 5.103
Authors: J L Gerin; H Alexander; J W Shih; R H Purcell; G Dapolito; R Engle; N Green; J G Sutcliffe; T M Shinnick; R A Lerner Journal: Proc Natl Acad Sci U S A Date: 1983-04 Impact factor: 11.205
Authors: Zhen-Yong Keck; Anne Op De Beeck; Kenneth G Hadlock; Jinming Xia; Ta-Kai Li; Jean Dubuisson; Steven K H Foung Journal: J Virol Date: 2004-09 Impact factor: 5.103
Authors: Fabrícia Gimenes; Raquel P Souza; Jaqueline C Bento; Jorge J V Teixeira; Silvya S Maria-Engler; Marcelo G Bonini; Marcia E L Consolaro Journal: Nat Rev Urol Date: 2014-10-21 Impact factor: 14.432